CC-4066 to prevent Delayed Graft Function

Delayed graft function (DGF) is a manifestation of acute kidney injury (AKI) following kidney transplantation. It manifests as an increase in serum creatinine and urea, decline in urine output and eventually requiring dialysis. DGF is a major obstacle to long-term graft survival, especially if compounded by acute rejection. Factors contributing to DGF include type of organ donor, preservation techniques, and the recipient’s response to reperfusion. It is the recipient’s innate immune response that causes sustained reperfusion injury.

CC-4066 is an intravenously administered small molecule scheduled to enter Phase II trials in Q3 2022 to prevent and/or treat acute kidney injury associated with transplantation. The compound has been shown to provide excellent protection against AKI induced by ischaemia, LPS or toxins in a number of preclinical animal models.